Financings In Brief

Pulmonx raises $32 million for emphysema device marketing: Overseas marketing of Pulmonx' Chartis pulmonary assessment system and Zephyr endobronchial valve for emphysema patients will be supported by a $32 million private equity financing, announced Feb. 22. Headquartered in Redwood City, Calif., Pulmonx "now plans to invest significantly to grow direct and indirect sales, marketing, and clinical development activities throughout the EU," the company says. Both of the devices are CE marked. Chartis launched in Europe last December through a network of distribution partners in key countries. Zephyr was acquired through Pulmonx' purchase of Emphasys Medical in May 2009 (1"The Gray Sheet" May 18, 2009). The recent financing was co-led by venture capital firm HealthCap and Kleiner Perkins Caufield & Byers. "The company expects that this round of financing will fund the expansion of its commercial operations through to positive cash flow and profitability," Pulmonx notes